Diffuse and persistent blood-spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells

Exp Neurol. 2015 May:267:152-64. doi: 10.1016/j.expneurol.2015.03.001. Epub 2015 Mar 12.

Abstract

Intravenous infusion of mesenchymal stem cells (MSCs) has been shown to reduce the severity of experimental spinal cord injury (SCI), but mechanisms are not fully understood. One important consequence of SCI is damage to the microvasculature and disruption of the blood spinal cord barrier (BSCB). In the present study we induced a contusive SCI at T9 in the rat and studied the effects of intravenous MSC infusion on BSCB permeability, microvascular architecture and locomotor recovery over a 10week period. Intravenously delivered MSCs could not be identified in the spinal cord, but distributed primarily to the lungs where they survived for a couple of days. Spatial and temporal changes in BSCB integrity were assessed by intravenous infusions of Evans blue (EvB) with in vivo and ex vivo optical imaging and spectrophotometric quantitation of EvB leakage into the parenchyma. SCI resulted in prolonged BSCB leakage that was most severe at the impact site but disseminated extensively rostral and caudal to the lesion over 6weeks. Contused spinal cords also showed an increase in vessel size, reduced vessel number, dissociation of pericytes from microvessels and decreases in von Willebrand factor (vWF) and endothelial barrier antigen (EBA) expression. In MSC-treated rats, BSCB leakage was reduced, vWF expression was increased and locomotor function improved beginning 1 week post-MSC infusion, i.e., 2weeks post-SCI. These results suggest that intravenously delivered MSCs have important effects on reducing BSCB leakage which could contribute to their therapeutic efficacy.

Keywords: Blood spinal cord barrier; Mesenchymal stem cell; Pericytes; Spinal cord injury.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antigens, Surface / metabolism
  • Blood-Brain Barrier / physiopathology*
  • Cell- and Tissue-Based Therapy*
  • Disease Models, Animal
  • Endothelial Cells / pathology
  • Exploratory Behavior
  • Glial Fibrillary Acidic Protein / metabolism
  • Locomotion / physiology
  • Male
  • Mesenchymal Stem Cells / physiology*
  • Microvessels / pathology
  • Permeability
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Transgenic
  • Receptor, Platelet-Derived Growth Factor beta / metabolism
  • Spinal Cord Injuries / pathology*
  • Spinal Cord Injuries / therapy*
  • Time Factors
  • von Willebrand Factor / metabolism

Substances

  • Antigens, Surface
  • Glial Fibrillary Acidic Protein
  • endothelial barrier antigen, rat
  • von Willebrand Factor
  • Receptor, Platelet-Derived Growth Factor beta